Randomized trial evaluates hydrogen biomethanation efficiency in anaerobic reactors, highlighting methane production potential.
Ex situ hydrogen biomethanation represents a promising approach to converting surplus renewable electricity into CH4-rich gas through the biological reduction in CO2 with H2, mediated by hydrogenotrophic methanogens. In this study, an ex situ H2 biomethanation process was investigated in a lab-scale mesophilic anaerobic reactor operated in fed-batch mode. The system followed a cyclic operational strategy comprising sequential gas feeding, reaction, and discharge phases. Hydrogen was supplied through a pressure-controlled feeding strategy, whereas CO2 injection maintained dissolved CO2 concentrations at 25, 17, and 2 mg L−1 during the initial, intermediate, and final stages, respectively. During early operation, volatile fatty acids (VFAs) temporarily accumulated to 3 g L−1, accompanied by a decrease in pH. Progressively lowering the dissolved CO2 target restored process stability, reduced the VFA concentration to 618 mg L−1, and increased the pH to 7.6. Under stable final-stage conditions, the reactor achieved an average CH4 concentration of 93.3%, a hydrogen utilization efficiency of 99%, and a methane evolution rate (MER) of 3.95 NL CH4 LVR−1 d−1. These results show that combining pressure-controlled hydrogen injection with dissolved CO2 regulation enhances methane production and maintains stable ex situ biomethanation.
No takes yet. Share an insight, caveat, or question.
Sharifi et al. (2026) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: